Legal Ipamorelin
Which rules govern Ipamorelin?
A sports laboratory can identify it. Sport prohibits it. FDA has never approved it. The word legal needs a much more specific question.
The urine-testing paper
In 2012, a sports drug-testing paper included Ipamorelin in a screen for 11 prohibited peptides in human urine. The method combined liquid chromatography, which separates a sample's components, with mass spectrometry to identify them. Across the assay, the reported limits of detection were 2–10 pg/mL.
The assay's precision appeals to me: can the laboratory identify the substance? There is a firm, technical answer. Ask whether the substance improves someone's health, or whether a particular preparation can lawfully be compounded, and the answer requires an entirely different record.
That is the trouble with calling Ipamorelin legal. The word sounds like a single permission slip. Approval, pharmacy compounding and eligibility in sport each have their own requirements. I distrust any reassurance that slides between them without saying so.
FDA approval and compounding
Ipamorelin has no FDA-approved indication. Its published Phase 2 trial in bowel-resection patients missed its primary endpoint. A compounding review asks a separate question about preparing a drug from a bulk substance; it does not supply the missing approval.
On FDA's page current as of April 22, 2026, Ipamorelin acetate remains in Category 2 under the 503B interim policy for outsourcing facilities. It also appears in the separate table of substances nominated but withdrawn. FDA gives no date for that withdrawal.
The October 29, 2024 Pharmacy Compounding Advisory Committee voted against adding both the free base and acetate to the 503A Bulks List. The legal-record notes unpack those entries. For me, that withdrawn nomination is the easiest detail to misread: a request disappearing from consideration offers very little reassurance about the substance itself.
Ipamorelin in sport
The WADA Prohibited List covers Ipamorelin under S2, the category for peptide hormones, growth factors, related substances and mimetics. It is prohibited at all times. The urine assays explain how analytical laboratories can look for it.
Even a convincing new patient result would leave me checking the sports prohibition separately. Detection research demonstrates an ability to identify a compound in a sample. It supplies no verdict on improved performance, useful treatment or long-term safety.
The benefit question
The pharmacology deserves more than a dismissive shrug. The original work showed selective growth-hormone release in rat cells, rats and swine. Later, mice gained fat even when growth hormone was deficient. Those findings make Ipamorelin interesting, and make the easy fat-loss story difficult to defend.
The narrow hormone result impresses me; I remain doubtful about better sleep, muscle or recovery. The benefits page follows those particular claims; safety and side effects deals with the short human trial, animal warnings and anecdotal reports. The dosage and half-life record stays with the amounts and timing actually studied.